The downgrade from Buy to Neutral by Mizuho indicates a less optimistic outlook for Arcutis Biotherapeutics. The significant reduction in price target from $57 to $4 suggests that the analyst believes the stock is overvalued at its current price, which could lead to a decrease in its stock price in the short term.